05:35 AM EDT, 05/24/2024 (MT Newswires) -- IN8bio ( INAB ) said late Thursday that it plans to release updated results from a phase 1 study of INB-200 showing improvement in progression-free survival in patients with newly diagnosed glioblastoma multiforme.

INB-200 is evaluating the autologous drug-resistant immunotherapy or chemotherapy-resistant gamma-delta T cells as a potential first-line treatment. The phase 1 study, fully enrolled, has 23 patients.

The company said data show most patients dosed exceeded the expected median progression-free survival of 7 months with Stupp therapy alone. Long-term follow-up for the durability of progression-free survival and overall survival is continuing. The current standard treatment has failed to advance progression-free survival beyond 4 to 7 months or overall survival beyond 14 to 16 months for over two decades.

The company found no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity in the phase 1 data, which it plans to release at a conference in Chicago from May 31 to June 4.

Price: 1.0700, Change: +0.03, Percent Change: +2.89